Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (92)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Longini, I. M.
Right arrow Articles by Yang, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Longini, I. M., Jr.
Right arrow Articles by Yang, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Am J Epidemiol 2004; 159:623-633.
Copyright © 2004 by the Johns Hopkins Bloomberg School of Public Health


SPECIAL ARTICLE

Containing Pandemic Influenza with Antiviral Agents

Ira M. Longini, Jr. , M. Elizabeth Halloran, Azhar Nizam and Yang Yang

From the Department of Biostatistics, The Rollins School of Public Health, Emory University, Atlanta, GA.

For the first wave of pandemic influenza or a bioterrorist influenza attack, antiviral agents would be one of the few options to contain the epidemic in the United States until adequate supplies of vaccine were available. The authors use stochastic epidemic simulations to investigate the effectiveness of targeted antiviral prophylaxis to contain influenza. In this strategy, close contacts of suspected index influenza cases take antiviral agents prophylactically. The authors compare targeted antiviral prophylaxis with vaccination strategies. They model an influenza pandemic or bioterrorist attack for an agent similar to influenza A virus (H2N2) that caused the Asian influenza pandemic of 1957–1958. In the absence of intervention, the model predicts an influenza illness attack rate of 33% of the population (95% confidence interval (CI): 30, 37) and an influenza death rate of 0.58 deaths/1,000 persons (95% Cl: 0.4, 0.8). With the use of targeted antiviral prophylaxis, if 80% of the exposed persons maintained prophylaxis for up to 8 weeks, the epidemic would be contained, and the model predicts a reduction to an illness attack rate of 2% (95% Cl: 0.2, 16) and a death rate of 0.04 deaths/1,000 persons (95% CI: 0.0003, 0.25). Such antiviral prophylaxis is nearly as effective as vaccinating 80% of the population. Vaccinating 80% of the children aged less than 19 years is almost as effective as vaccinating 80% of the population. Targeted antiviral prophylaxis has potential as an effective measure for containing influenza until adequate quantities of vaccine are available.

antiviral agents; bioterrorism; computer simulation; disease outbreaks; influenza; influenza A virus; influenza vaccine; Monte Carlo method

Abbreviations: Abbreviations: AVE, antiviral efficacy; AVED, antiviral efficacy for symptomatic disease given infection; AVEI, antiviral efficacy for infectiousness; AVES, antiviral efficacy for susceptibility to infection; AVESD, antiviral efficacy for symptomatic disease; CI, confidence interval; R, reproductive number; R0, basic reproductive number; VEI, vaccine efficacy for infectiousness; VES, vaccine efficacy for susceptibility; VEIII, overall effectiveness.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Nuno, T. A. Reichert, G. Chowell, and A. B. Gumel
Protecting residential care facilities from pandemic influenza
PNAS, July 29, 2008; 105(30): 10625 - 10630.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
F. Carrat, E. Vergu, N. M. Ferguson, M. Lemaitre, S. Cauchemez, S. Leach, and A.-J. Valleron
Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies
Am. J. Epidemiol., April 1, 2008; 167(7): 775 - 785.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. E. Halloran, N. M. Ferguson, S. Eubank, I. M. Longini Jr., D. A. T. Cummings, B. Lewis, S. Xu, C. Fraser, A. Vullikanti, T. C. Germann, et al.
Modeling targeted layered containment of an influenza pandemic in the United States
PNAS, March 25, 2008; 105(12): 4639 - 4644.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
E. Lofgren, N. H. Fefferman, Y. N. Naumov, J. Gorski, and E. N. Naumova
Influenza Seasonality: Underlying Causes and Modeling Theories
J. Virol., June 1, 2007; 81(11): 5429 - 5436.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. P. Galvani, T. C. Reluga, and G. B. Chapman
Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum
PNAS, March 27, 2007; 104(13): 5692 - 5697.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
M. E. Halloran, F. G. Hayden, Y. Yang, I. M. Longini Jr, and A. S. Monto
Antiviral Effects on Influenza Viral Transmission and Pathogenicity: Observations from Household-based Trials
Am. J. Epidemiol., January 15, 2007; 165(2): 212 - 221.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
M. E. Halloran
Invited Commentary: Challenges of using Contact Data to Understand Acute Respiratory Disease Transmission
Am. J. Epidemiol., November 15, 2006; 164(10): 945 - 946.
[Full Text] [PDF]


Home page
Am J EpidemiolHome page
J. Wallinga, P. Teunis, and M. Kretzschmar
Using Data on Social Contacts to Estimate Age-specific Transmission Parameters for Respiratory-spread Infectious Agents
Am. J. Epidemiol., November 15, 2006; 164(10): 936 - 944.
[Abstract] [Full Text] [PDF]


Home page
Stat Methods Med ResHome page
F. Ball and O. Lyne
Optimal vaccination schemes for epidemics among a population of households, with application to variola minor in Brazil
Statistical Methods in Medical Research, October 1, 2006; 15(5): 481 - 497.
[Abstract] [PDF]


Home page
J. Epidemiol. Community HealthHome page
A. Doyle, I. Bonmarin, D. Levy-Bruhl, Y. L. Strat, and J.-C. Desenclos
Influenza pandemic preparedness in France: modelling the impact of interventions
J. Epidemiol. Community Health, May 1, 2006; 60(5): 399 - 404.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. C. Germann, K. Kadau, I. M. Longini Jr., and C. A. Macken
From the Cover: Mitigation strategies for pandemic influenza in the United States
PNAS, April 11, 2006; 103(15): 5935 - 5940.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
R. K. Plemper, J. Doyle, A. Sun, A. Prussia, L.-T. Cheng, P. A. Rota, D. C. Liotta, J. P. Snyder, and R. W. Compans
Design of a Small-Molecule Entry Inhibitor with Activity against Primary Measles Virus Strains
Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3755 - 3761.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
I. M. Longini Jr., A. Nizam, S. Xu, K. Ungchusak, W. Hanshaoworakul, D. A. T. Cummings, and M. E. Halloran
Containing Pandemic Influenza at the Source
Science, August 12, 2005; 309(5737): 1083 - 1087.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
I. M. Longini Jr. and M. E. Halloran
Strategy for Distribution of Influenza Vaccine to High-Risk Groups and Children
Am. J. Epidemiol., February 15, 2005; 161(4): 303 - 306.
[Abstract] [Full Text] [PDF]


Home page
J. Epidemiol. Community HealthHome page
G. Rezza
Avian influenza: a human pandemic threat?
J. Epidemiol. Community Health, October 1, 2004; 58(10): 807 - 808.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.